1. Scrip
  2. >>Business
  3. >>Financing

Sonoma Bio Raises $265m To Test T-regs In Autoimmune Diseases

First Indication Is RA, But IBD Is Another Opportunity

 
• By Mandy Jackson

The company will determine whether a single administration of autologous regulatory T-cells (Tregs) can reset and restore immune tolerance in autoimmune, inflammatory and neuroinflammatory diseases.

Young woman with rheumatoid arthritis deformed fingers
Sonoma Bio's T-reg therapies may offer a polypharmacy approach to treating rheumatoid arthritis and other autoimmune diseases • Source: Alamy

Sonoma Biotherapeutics revealed a $265m series B venture capital round on 4 August that will fund the first clinical trials of its autologous regulatory T-cell (Treg) therapies to test whether the company can deliver a one-time treatment with the ability to restore immune system balance in autoimmune diseases and inflammation, including neuroinflammation. Sonoma Bio’s lead Treg program is designed to treat rheumatoid arthritis, but it is also investigating Tregs for inflammatory bowel diseases.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down

 
• By Mandy Jackson

Restructuring Edition: ESSA and Elevation are reviewing strategic alternatives after trial failures, but each has an investor urging them to liquidate. Also, Third Harmonic and Vincerx are winding down, while Keros and Tempest are assessing options, but Opthea and OPM are cutting jobs.

Finance Watch: Biopharma Sees An Early April VC Mega-Round Surge

 
• By Mandy Jackson

Private Company Edition: After Q1 venture capital investment slumped relative to 2024 totals due to declines in both smaller financings and mega-rounds, Q2 started off with six $100m-plus financings in the first half of April after there were only three in February and six in all off March.

Glycomine Funds Phase IIb Rare Disease Trial With $115m Series C

 
• By Mandy Jackson

Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

More from Business

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.